Latest News by Industry
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming conferences.
Conference: CPHI Frankfurt
Date: November 1-3, 2022
Location: Frankfurt, Germany
Pluri’s Chief Commercial Officer, Nimrod Bar Zvi, and VP Business Development, Efrat Kaduri, will attend CPHI Frankfurt.
CPHI Frankfurt brings together pharma industry participants from across the full supply chain, to source, connect, and help their businesses grow.
Conference: Jefferies London Healthcare Conference 2022
Date: November 15-17, 2022
Location: London, England
Pluri’s Chief Financial Officer, Chen Franco-Yehuda will attend the conference.
The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe. The conference will feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.
Conference: Challenges and Opportunities for Mesenchymal Stem Cells
Date: November 17-19, 2022
Location: Virtual
Pluri’s Chief Medical Officer, Nitsan Halevy, will be a Panelist on November 17th from 8:05 am – 8:50 am for the panel titled: What are the Current Barriers for Success?
Pluri’s Chief Technology Officer, Lior Raviv, will be giving a presentation titled: Scalability of MSC Production to aid Logistical Burdens, on November 18th from 9:20am - 9:50am.
The conference’s focus is—Bench to bedside: Address underserved disease areas with innovative approaches to improve regulatory outcomes, scale-up strategies, cryopreservation techniques & logistical planning.
Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at info@pluri-biotech.com
About Pluri Inc.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and biologics and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Nathan Miller at nathan@miller-ink.com / Meira Feinman at meira@miller-ink.com